-Advertisement-
-Advertisement-
FDA Alerts

FDA approves momelotinib for myelofibrosis patients with anemia
The US Food and Drug Administration has approved momelotinib (Ojjaara; GSK) for treating intermediate or high-risk myelofibrosis in adults with anemia, according to a press release. It is currently the only approved medication for both newly diagnosed and previously treated myelofibrosis patients with anemia, effectively addressing major symptoms of the disease...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved